- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance-Touted as a new "DeepSeek Moment" in Precision Oncology | 13 | GlobeNewswire (USA) | ||
| 01.07. | BioNexus Gene Lab Stock Soars 239% | 15 | RTTNews | ||
| 23.06. | BioNexus Gene Lab Corp - 8-K, Current Report | 10 | SEC Filings | ||
| 30.04. | BioNexus Gene Lab erlangt NASDAQ-Konformität wieder | 9 | Investing.com Deutsch | ||
| BIONEXUS GENE LAB Aktie jetzt für 0€ handeln | |||||
| 30.04. | BioNexus Gene Lab regains Nasdaq compliance | 1 | Investing.com | ||
| 30.04. | BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness | 176 | GlobeNewswire (Europe) | KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today... ► Artikel lesen | |
| 30.04. | BioNexus Gene Lab Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 29.04. | BioNexus Gene Lab Corp - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 15.04. | BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory | 172 | GlobeNewswire (Europe) | KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered... ► Artikel lesen | |
| 15.04. | BioNexus Gene Lab Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.04. | BioNexus Gene Lab Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 03.04. | BioNexus Gene Lab announces reverse stock split | 1 | Investing.com | ||
| 03.04. | BioNexus Gene Lab Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 25.03. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Krypto-Revolution: BioNexus schreibt Geschichte: Ethereum triumphiert über Bitcoin! | 4.650 | wallstreetONLINE | © Foto: Jakub Porzycki - NurPhotoBioNexus setzt als erstes Nasdaq-Unternehmen auf Ethereum statt Bitcoin und wagt trotz finanzieller Herausforderungen einen kühnen Schritt in die Krypto-Zukunft.Die... ► Artikel lesen | |
| 06.03. | Krypto-Revolution: Ethereum statt Bitcoin: Nasdaq-Unternehmen BioNexus schreibt Krypto-Geschichte! | 1.034 | wallstreetONLINE | © Foto: Jakub Porzycki - NurPhotoBioNexus setzt als erstes Nasdaq-Unternehmen auf Ethereum statt Bitcoin und wagt trotz finanzieller Herausforderungen einen kühnen Schritt in die Krypto-Zukunft.Die... ► Artikel lesen | |
| 06.03. | BioNexus Stock Pops As It Embraces Ethereum-Focused Treasury Strategy, Says It Is First On Nasdaq To Do So | 5 | Benzinga.com | ||
| 05.03. | BioNexus Gene Lab adopts Ethereum for treasury strategy | 4 | Investing.com | ||
| 05.03. | BioNexus Gene Lab Corp - 8-K, Current Report | 7 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DRAEGERWERK | 67,00 | +0,60 % | Draegerwerk AG & Co. KGaA: Dräger bestätigt Q2-Trends und starker Auftragseingang unterstützt Visibilität. HALTEN. | Dräger bestätigt die Ergebnisse für das 2. Quartal 2025 mit einem Umsatzanstieg von 1,8% (wb.) auf 780 Mio EUR und einem EBIT von 20 Mio EUR, was den Wegfall von Einmalerträgen aus dem Vorjahr widerspiegelt.... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,110 | -6,78 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,701 | +3,55 % | RedChip Companies, Inc.: Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip... ► Artikel lesen | |
| PING AN HEALTHCARE | 1,370 | +2,78 % | PA GOODDOCTOR (01833): NOTICE OF BOARD MEETING | ||
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,004 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| CO-DIAGNOSTICS | 0,208 | 0,00 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 0,854 | +8,93 % | Cytosorbents Corp: CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR | PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions... ► Artikel lesen | |
| VERU | 0,323 | +3,06 % | Veru Inc.: Veru Announces Reverse Stock Split | MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
| VOLITIONRX | 0,668 | 0,00 % | VolitionRx prices $1.2M registered direct offering | ||
| EKSO BIONICS | 3,250 | -1,22 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| IMUNON | 5,970 | -15,32 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
| BEYOND AIR | 2,800 | 0,00 % | Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc. | GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
BIONEXUS GENE LAB CORP gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 5,530 Euro und damit -1,07 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIONEXUS GENE LAB CORP finden Sie auf Wallstreet Online.